Hydrocodone Combination Up-scheduling Marches Forward Despite FDA Ambivalence
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Drug Safety and Risk Management Advisory Committee votes 19-10 to move the opioid drugs to the more restrictive Schedule II because their abuse potential is similar to other drugs already that already have the controlled substances designation.